key: cord-0940746-wbe2oi3m authors: Salvarani, Carlo; Massari, Marco; Costantini, Massimo; Franco Merlo, Domenico; Lucia Mariani, Gabriella; Viale, Pierluigi; Nava, Stefano; Guaraldi, Giovanni; Dolci, Giovanni; Boni, Luca; Savoldi, Luisa; Bruzzi, Paolo; Turrà, Caterina; Catanoso, Mariagrazia; Maria Marata, Anna; Barbieri, Chiara; Valcavi, Annamaria; Franzoni, Francesca; Cavuto, Silvio; Mazzi, Giorgio; Corsini, Romina; Trapani, Fabio; Bartoloni, Alessandro; Barisione, Emanuela; Barbieri, Chiara; Jole Burastero, Giulia; Pan, Angelo; Inojosa, Walter; Scala, Raffaele; Burattini, Cecilia; Luppi, Fabrizio; Codeluppi, Mauro; Eldin Tarek, Kamal; Cenderello, Giovanni; Salio, Mario; Foti, Giuseppe; Dongilli, Roberto; Bajocchi, Gianluigi; Alberto Negri, Emanuele; Ciusa, Giacomo; Fornaro, Giacomo; Bassi, Ilaria; Zammarchi, Lorenzo; Aloè, Teresita; Facciolongo, Nicola title: Intravenous methylprednisolone pulses in hospitalised patients with severe COVID-19 pneumonia, A double-blind, randomised, placebo-controlled trial date: 2022-03-31 journal: Eur Respir J DOI: 10.1183/13993003.00025-2022 sha: cca46d6c0c106af334e151737ad147cb2e7c2e1c doc_id: 940746 cord_uid: wbe2oi3m RATIONALE: Pulse glucocorticoid therapy is used in hyperinflammation related to coronavirus 2019 (COVID-19). We evaluated the efficacy and safety of pulse intravenous methylprednisolone in addition to standard treatment in COVID-19 pneumonia. METHODS: In this multicenter, randomised, double-blind, placebo-controlled trial, 304 hospitalised patients with Covid-19 pneumonia were randomised to receive 1 g of methylprednisolone intravenously for 3 consecutive days or placebo in addition to standard dexamethasone. The primary outcome was the duration of the patient hospitalisation, calculated as the time interval between randomisation and hospital discharge without the need of supplementary oxygen. The key secondary outcomes were survival free from invasive ventilation with orotracheal intubation and overall survival. RESULTS: Overall, 112 of 151 (75.4%) patients in the pulse methylprednisolone arm and 111 of 150 (75.2%) in the placebo arm were discharged from hospital without oxygen within 30 days from randomisation. Median time to discharge was similar in both groups [15 days (95% confidence interval (CI), 13.0 to 17.0) and 16 days (95%CI, 13.8 to 18.2); hazard ratio (HR), 0.92; 95% CI 0.71–1.20; p=0.528]. No significant differences between pulse methylprednisolone and placebo arms were observed in terms of admission to Intensive Care Unit with orotracheal intubation or death (20.0% versus 16.1%; HR, 1.26; 95%CI, 0.74–2.16; p=0.176), or overall mortality (10.0% versus 12.2%; HR, 0.83; 95%CI, 0.42–1.64; p=0.584). Serious adverse events occurred with similar frequency in the two groups. CONCLUSIONS: Methylprenisolone pulse therapy added to dexamethasone was not of benefit in patients with COVID-19 pneumonia. MESSAGE OF THE STUDY: Pulse glucocorticoid therapy is used for severe and/or life threatening immuno-inflammatory diseases. The addition of pulse glucocorticoid therapy to the standard low dose of dexamethasone scheme was not of benefit in patients with COVID-19 pneumonia. . Glucocorticoids for their broad and rapid anti-inflammatory effects are ideal candidates for the treatment of hyperinflammation in COVID-19 (2) (3) (4) . Interestingly, Fauci and coworkers in the 70s showed that glucocorticoids block inflammation by inhibiting the efflux of neutrophils and monocytes to the inflammatory sites (5) . Both cell types play an important role in COVID- 19-induced lesions, both in the peripheral blood and lungs (3, 6) . The Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial showed that low-dose dexamethasone reduced mortality in hospitalized patients with COVID-19 requiring respiratory support (7) . This observation was confirmed by a prospective meta-analysis of 7 randomized trials in severe COVID-19 patients which showed that the administration of systemic glucocorticoids, compared with usual care or placebo, was associated with lower 28day all-cause mortality and that it was also safe (8) . Pulse glucocorticoid therapy (> 250 mg of prednisone equivalent per day for 1 or a few days) has the most relevant genomic and nongenomic actions, that are responsible for the anti-inflammatory and rapid effects of glucocorticoids, therefore this treatment modality is used for particularly severe and/or life threatening immuno-inflammatory diseases as initial therapy (9) (10) (11) (12) . In COVID-19 the cytokine storm represents the acme of the inflammatory process, suggesting the need for a prompt and strong anti-inflammatory effect. Therefore, the addition of pulse glucocorticoid therapy to the standard low dose of dexamethasone scheme can suppresses the hyperinflammatory processes in COVID-19 more effectively than dexamethasone alone and may represent a potential treatment option for patients with severe and critical COVID-19, where pulse glucocorticoid therapy can provide better alternative than non-pulse treatment. No double-blind randomized trials have been conducted to assess the efficacy of the addition of steroid pulse therapy to the available usual care for COVID-19 pneumonia. To evaluate the efficacy and safety of pulse intravenous methylprednisolone therapy in hospitalized patients with COVID-19 pneumonia, we conducted a multicenter, randomized, double-blind, placebo-controlled trial. This is a multicenter, randomized, double-blind, placebo-controlled trial coordinated by the Azienda Unità Sanitaria Locale-IRCCS of Reggio Emilia, Italy. Nineteen Italian centres participated to this trial. The trial was submitted and approved on November 20, 2020, by the Italian Medicines Agency (AIFA) (code 130662) and on November 25, 2020, by the COVID- 19 Ethics Committee established at the National Institute for Infectious Diseases, Lazzaro Spallanzani, Rome (code 217). The trial was conducted in accordance with the principles of the Good Clinical Practice guidelines of the International Conference on Harmonization. The trial was overseen by an independent data safety and monitoring committee. Written informed consent was obtained from each patient or from the patient's legally authorized representative if the patient was unable to provide consent. Full details of the trial design, conduct, oversight, and analyses can be found in the protocol, statistical analysis plan, and supplementary appendix. The study population included patients hospitalized for recent-onset COVID-19 pneumonia documented by radiological imaging, with more than five days since initial symptoms of infection, requiring supplemental oxygen in any delivery mode, except invasive mechanical ventilation, with PaO 2 /FiO 2 between 100 and 300, and a C-reactive protein (CRP) greater than 5 mg/dL. This CRP value was selected because this cut-off on admission is an indicator of COVID-19 disease severity associated with increased mortality in hospitalized patients (13) . Cases of COVID-19 were confirmed by polymerase chain reaction method with nasopharyngeal swab. Patients were excluded if they required invasive mechanical ventilation or in the presence of shock or concomitant organ failure requiring an Intensive Care Unit (ICU) admittance. Other exclusion criteria were pregnancy or breastfeeding, severe cardiac or renal failure, diabetes not in good metabolic control based on physician's clinical judgment and other clinical conditions which contraindicate methylprednisolone and which cannot be treated or resolved based on physician's clinical judgment. Therapy with steroid high dose pulses in the week preceding the enrolment in the study and enrolment in another clinical trial were also exclusion criteria. Eligible patients were randomly assigned in 1:1 ratio to receive either methylprednisolone pulse therapy or placebo, in both arms in addition to standard treatment with dexamethasone. Random assignment was performed centrally at the Trials Center of the Policlinico San Martino-IRCCS in Genova, Italy, stratified by participating centers and type of noninvasive respiratory support [standard oxygen versus High Flow Nasal Cannula (HFNC) or noninvasive ventilation (NIV)]. Computer generated random lists were prepared using permuted balanced blocks of size 4 in random sequence. An Internet-based randomization system ensured concealment of the treatment assignment until the patient had been registered in the system. Treatment allocation was communicated electronically only to the study center's pharmacy to allow local preparation of the methylprednisolone or placebo bag for the IV administration of the treatment. Patients in the experimental arm received 3 boluses of 1 g of methylprednisolone intravenously on days 1, 2 and 3 from randomization in 100 ml physiological in addition to standard treatment. Patients in the control arm received 100 ml of saline (placebo) administered on days 1, 2 and 3 from randomization in addition to standard treatment. Standard treatment included dexamethasone (6 mg / day oral or intravenous for 10 days), according to the RECOVERY study protocol (2) . The standard therapy was allowed to change during the study in accordance with the indications of the Italian Medicines Agency (AIFA) cards regarding the choice of drugs, dosages, or duration of treatment. Patients were evaluated daily during their hospitalization, from randomization (day 1) through day 30. The type of noninvasive respiratory support was daily recorded. The medical evaluations on day 21, 28 and end of study (30 days) could be limited to a telephone contact if the patient was at home. The compilation of the end of study visit was mandatory and it could coincide with any clinical visit or telephone contact occurred during the 30 days' observation window. All the severe and non-severe adverse events observed during the hospitalization and in the 30 days from randomization were recorded in the clinical database. Adverse events were classified and graded according to the Common Terminology Criteria for Adverse Events (CTCAE) v 5.0 criteria. For each adverse event the maximum grade of toxicity was identified. Trial participants, investigators, study team care providers were unaware of the trial-group assignments until after all data queries were resolved and the database was locked. Only the hospital pharmacies were aware of the treatment allocation. The primary endpoint was the duration of the patient hospitalization, calculated as the interval of time between the randomization and the hospital discharge without the need of supplementary oxygen during the first 30 days following randomization. The patients who were transferred to other hospital wards at different intensity of care were considered as still hospitalized. Patients who were transferred to other institutions outside the hospital (e.g., COVID-hotels) for the impossibility of transferring the patient at home were considered as discharged from the hospital. Patients deceased within 30 days were considered as never discharged. Patients discharged at home with supplementary oxygen were censored at the date of discharge because no further follow-up information was available. This choice implied the questionable assumption that their prognosis was similar to that of patients still in hospital: the effects of this assumption were evaluated in 2 post-hoc sensitivity analyses in which these patients were considered either discharged without oxygen, or never discharged. The results of these analyses closely resembled those of the primary analysis. The secondary endpoints of efficacy were the following: Survival free from invasive ventilation with orotracheal intubation, defined as the interval between the randomization and the first use of invasive ventilation with orotracheal intubation or death. Overall survival, defined as the interval between randomization and death for any cause. According to the study protocol, the following explorative endpoints were also evaluated in selected populations: 1. Survival free from clinical worsening, defined as the interval between randomization and the first episode in which the ratio PaO 2 /FiO 2 drops below the value 150 or death. Only patients with PaO 2 /FiO 2 , > 200 mm Hg at enrolment were included in this analysis. Survival free from NIV or HFNC, defined as the interval between randomization and the first use of NIV or the first administration of HFNC, or death. Only patients who did not receive oxygen in this modality at randomization were included in this analysis. Assuming a median time to hospital discharge of 14 days in the control arm, the experimental treatment was considered effective if it reduced time to discharge by 37.5% in relative terms (hazard ratio = 1.60). This corresponds to an absolute increase in the cumulative probability of discharge at 14 days from 50% to 67%, i.e., a decrease in the median time to discharge from 14 to less than 9 days. Assuming a statistical power of 90% and a 5% error rate α, for a two-tailed log rank test at least 198 hospital discharges needed to be observed. The sample size required to observe 198 hospital discharges, assuming a 5% overall dropout rate, was estimated to be at least 260 patients, 130 per arm. Statistical analysis is detailed in the Statistical Analysis Plan. The cumulative probabilities of survival free from discharge in the two treatment groups were estimated according to the Kaplan Meier method and compared with a nonstratified log rank test. The hazard ratio and its 95% confidence interval (95%CI) were computed by fitting a univariate Cox's model. All secondary efficacy analyses were performed with the same approach described for the primary efficacy analysis. Primary and secondary efficacy analyses were performed on all patients included in the intention-to-treat population. Explorative endpoints analyses were carried out on the appropriate sub-populations, identified from the intention-to-treat population. We reported the P value (2 tailed; significance defined as P<0.05) and bilateral 95%CI not adjusted for multiplicity. Plan that we reported into the Appendix. Table 1 . One (Table 3) (Table 3) . A summary description of SAEs is reported in the Appendix. Bacterial infections were the most frequently reported severe adverse events in both arms and they were detailed in Table S2 . In particular, serious infections thought to be related to the treatment were observed in 3.3% of the patients treated with methylprednisolone pulses and in 4% of those treated with placebo. Cases of severe uncontrolled hyperglycemia were not reported in the two arms. In this double-blind, randomized, placebo-controlled trial no significant difference was observed in time to hospital discharge between the high-dose Despite the overall negative results of our study, we cannot exclude potential benefit in specific subgroups of patients with more severe disease and more severe inflammatory response. Also, our study cannot rule out a role for pulse glucocorticoid therapy as a rescue therapy in patients who failed to improve after dexamethasone and that a gradual tapering of pulse methylprednisolone would have better controlled the inflammation, avoiding possible rebound. Of interest, our study did not show an increased risk of glucocorticoid side effects, particularly infections or hyperglycemia, in the patients treated with methylprednisolone pulses. Previous studies observed only an increased frequency of mild acute adverse events (e.g., sleep disturbance, mood change) in patients treated with pulse glucocorticoids compared to those treated with placebo (10, 12) . Therefore, our results confirm that pulses of methylprednisolone are safe also in the inflammatory phase of patients with COVID-19. Our trial has some strengths, but also some limitations. One of the strengths is that Table S4 : Clinical outcomes at 30 days according the modality of oxygen administration at randomisation Table S5 : Clinical outcomes at 30 days according to C-reactive protein (CPR) at randomisation (The list was ordered by number of patients enrolled) The following institutions were involved in this study. For each institution the study group members involved with the design and implementation of the study are reported. Azienda USL -IRCCS di Reggio Emilia: Other data about safety In these subgroup analyses Hazard ratios (HRs) estimates obtained in the Cox model were reported within each subgroup, while the presence of a significant variation of the HRs across strata of each factor was assessed by means of the appropriate treatment-by-factor interaction tests. The P values of the interaction tests are reported, but should be considered with caution, due to the lack of correction for multiplicity. Discharge without oxygen Discharge without oxygen Discharge without oxygen Current evidence for COVID-19 therapies: a systematic literature review Antiinflammatory action of glucocorticoids--new mechanisms for old drugs Immunopathology of Hyperinflammation in COVID-19 Acute-phase reactants during tocilizumab therapy for severe COVID-19 pneumonia Glucocorticosteroid therapy: mechanisms of action and clinical considerations Altered bioenergetics and mitochondrial dysfunction of monocytes in patients with COVID-19 pneumonia Dexamethasone in Hospitalized Patients with Covid-19 WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Metaanalysis Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action Pulse glucocorticoid therapy. The 'big shot' revisited The big shot Pulse steroid therapy The role of Creactive protein as a prognostic marker in COVID-19 Online ahead of print. 15. Woods JE, Anderson CF, DeWeerd JH et al. High-dosage intravenously administered methylprednisolone in renal transplantation: a preliminary report Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebocontrolled, randomized prospective clinical trial Double-blind trial of dexamethasone versus methylprednisolone in multiple sclerosis acute relapses Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial Effect of high versus low dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 Pneumonia: an open-label, randomised clinical trial Tests for interaction for discharge without oxygen (P=0.083), admission to ICU or death Tests for interaction for discharge without oxygen (P=0.822), admission to ICU or death Tests for interaction for discharge without oxygen (P=0.276), admission to ICU or death Clinical outcomes at 30 days according to the age at randomisation Strata:  Age (years) ≤ 60 (no. 120)  Age (years) > Tests for interaction for discharge without oxygen (P=0.435), admission to ICU or death Clinical outcomes at 30 days according to Body Mass Index at randomisation Strata:  BMI 1 st quartile  BMI 3 rd quartile Tests for interaction for discharge without oxygen (P=0.6071), admission to ICU or death We would like to thanks all patients for their participation in this important research. A special thank goes to the members of the AIFA Scientific Committee and COVID-19 Crisis Unit for their support. Gastrointestinal